Fosun Health Partners with Boston Scientific, Medtronic, and Alma Lasers to Advance Global Innovative Medical Technologies at CIIE

Through the "open window" of the CIIE, on November 6,Foshan Fosun Chancheng Hospital (hereinafter referred to as "Foshan Fosun Chan Hospital") under Fosun Health signed a strategic cooperation agreement with Boston Scientific and Medtronic., announcing the introduction of the FARAPULSE pulsed field ablation system for the treatment of atrial fibrillation and the Symplicity Spyral renal denervation system for the treatment of hypertension under the guidance of the "Hong Kong-Macao Medicine and Device Connect" policy.^TM。

In addition,Chongqing Xingrong Plastic Surgery Hospital under Fosun Health (hereinafter referred to as "Chongqing Xingrong") also signed a strategic cooperation agreement with Yaguang Medical Group on the same day.It was announced that the latest medical device developed by EMG Laser, a subsidiary of Y&G Holding(Guangdong) Co.,Ltd. in the UK, will complete GCP clinical trials at Chongqing Xingrong. The establishment of Chongqing Xingrong's dual GCP bases plays an important role in introducing international innovative technologies while developing medical product research, advancing the rapid development of the hospital’s academic research standards, promoting the hospital’s internal construction, and enhancing the overall strength of the hospital.

Chen Yuqing, Vice President of Fosun International and Chairman of Fosun Health, Hu Hang, CEO of Fosun Health and President of Foshan Fosun Chancheng Hospital, attended the relevant ceremony, jointly witnessing another significant moment for Fosun Health in leading the development and implementation of international innovative pharmaceuticals and medical devices.

"From the 'Hong Kong-Macao Medicine and Medical Device Access Program' officially implemented in 2021, to the recently released 'Management Requirements for Temporary Import and Use of Clinically Urgently Needed Medical Devices by Medical Institutions (Draft for Soliciting Opinions),' we can see that relevant policies are continuously activating the clinical initiative of medical service institutions. After implementing the 'Digital-Physical Healthcare' strategy and integrating the entire digital healthcare chain, Fosun Health has gained clinical insight and regulatory capabilities, objectively possessing the conditions to lead the development and implementation of innovative international medicines and medical devices." Chen Yuqing, Chairman of Fosun Health, emphasized,Marked by the signing of multiple strategic cooperation agreements at this CIIE, Fosun Health will continue to promote the development of clinical disciplines and meet the diverse medical needs of the public.

Unlike the conventional imported medical devices for which enterprises submit marketing applications, the implementation of the "Hong Kong-Macao Medicine and Device Connect" policy marks the development of an innovative review system and regulatory approach. A medicine and device management model driven by clinical needs is continuously evolving. "Against the backdrop of comprehensive integration policies in the Guangdong-Hong Kong-Macao Greater Bay Area, as the second batch of ‘Medicine and Device Connect’ hospitals in Guangdong Province and the first in Foshan, the two innovative medical devices signed and implemented with Foshan Fosun Chan Hospital at the CIIE were initiated and led by the relevant departments. Based on actual clinical needs, innovative medicines and devices are introduced under controllable risks, allowing patients' treatment options to rival international standards and providing more choices. This is precisely the significance of the new medicine and device management model," said Hu Hang, CEO of Fosun Health and President of Foshan Fosun Chan Hospital.

It is reported that, under the active promotion of multiple departments,Foshan Fosun Chan Medical Hospital has been approved for 5 Hong Kong-Macao medicine and device access products, with 4 products being introduced for the first time in Guangdong Province.Among them, the first prescriptions for the drugs Inclisiran and Rimegepant Sulfate Orally Disintegrating Tablets were issued on June 14 and September 22, respectively, at Foshan Chancheng Medical. As of now, dozens of patients have benefited from the Greater Bay Area Medicine and Device Pilot Policy.

For the regulation of corresponding pharmaceuticals and medical devices, Foshan Fosun Chanyi Hospital, empowered by Fosun Health's Smart Healthcare Cloud Platform (Cloud HIS), has established a "one item, one code" management model. By assigning unique codes to all specially approved pharmaceuticals and medical devices under the Greater Bay Area Medicines and Medical Devices Pass ("GAPMMD"), each smallest package of medicine and medical device is given a unique identification code. The hospital has also set up a special "GAPMMD Outpatient Clinic," implementing full-process closed-loop management. "Every step must be taken seriously—from procurement, transportation, usage, patient communication, informed consent, adverse event monitoring, to risk compensation. Especially during the use of medicines, the hospital must conduct strict monitoring," emphasized Tan Minghua, Vice President of Foshan Fosun Chanyi Hospital."Thanks to the continuous integration of digital technology and physical medical services by Fosun Health, we are able to implement multi-level authentication for patient prescriptions and long-term tracking of patient treatments, ensuring full-chain supervision of these clinically urgent innovative drugs and devices, ultimately achieving a high level of regulation with controllable risks and accountable responsibilities."

Using Foshan Fosun Chan Medical as a template, the regulatory system created by Fosun Health has also provided fertile ground for the implementation of innovative drugs and medical devices in its other hospitals. On March 22 and May 25 this year, Chongqing Xingrong successfully registered as a national medical device clinical trial institution and a drug clinical trial institution, respectively. It is also the first non-public medical institution in China to have a dual GCP base in medical aesthetics for both pharmaceuticals and medical devices. GCP (Good Clinical Practice) provides a unified quality standard for clinical trials, ensuring scientifically reliable results and safeguarding the rights, safety, and health of participants. The establishment of Chongqing Xingrong’s dual GCP base, supported by Fosun Health's robust regulatory system, will lead the cosmetic surgery industry in conducting research on related drugs and medical devices, becoming a model for the development of medical aesthetics in China.

Under the guidance of the "Hong Kong and Macao Medicine and Device Access" policy, using this CIIE as a platform,Fosun Health, starting from the Greater Bay Area, leads the implementation of innovative drugs and medical devices in clinical treatment while extending a healthcare service model of "talent exchange" and "information connectivity," building a stable healthcare service triangle model to achieve the goal of a "Healthy Greater Bay Area."

"We will use Foshan Fosun Chan Hospital, which has been approved under the Greater Bay Area (GBA) drug and medical device access policy, as a key pivot in the GBA. Together with multiple hospitals currently established by Fosun Health in the region, Fosun Health will continuously support the clinical application of Hong Kong and Macao drugs and medical devices in GBA hospitals. This support will focus particularly on talent and information sharing. Only by enabling the free flow of medical professionals within the GBA and ensuring the smooth exchange of patient diagnostic information can innovative drugs and medical devices achieve their optimal clinical outcomes, thereby better addressing the complex healthcare needs of patients today," explained Hu Hang.